212 related articles for article (PubMed ID: 32764876)
1. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
Miao M; Jing X; De Clercq E; Li G
Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
[TBL] [Abstract][Full Text] [Related]
2. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Gane EJ; Rouzier R; Hassanein T; Stedman CA; Mazur W; Kupcova V; Le Pogam S; Eng S; Voulgari A; Morcos PN; Brennan BJ; Scalori A; Thommes J
Hepatol Int; 2016 May; 10(3):478-87. PubMed ID: 26886127
[TBL] [Abstract][Full Text] [Related]
4. Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study.
Kao JH; Yu ML; Chen CY; Peng CY; Chen MY; Tang H; Chen Q; Wu JJ
J Gastroenterol Hepatol; 2018 Aug; 33(8):1507-1510. PubMed ID: 29346834
[TBL] [Abstract][Full Text] [Related]
5. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
Tong X; Li L; Haines K; Najera I
Antimicrob Agents Chemother; 2014 Jun; 58(6):3105-14. PubMed ID: 24637689
[TBL] [Abstract][Full Text] [Related]
6. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
Deutsch M; Papatheodoridis GV
Curr Opin Investig Drugs; 2010 Aug; 11(8):951-63. PubMed ID: 20721837
[TBL] [Abstract][Full Text] [Related]
7. Danoprevir: First Global Approval.
Markham A; Keam SJ
Drugs; 2018 Aug; 78(12):1271-1276. PubMed ID: 30117020
[TBL] [Abstract][Full Text] [Related]
8. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Marcellin P; Cooper C; Balart L; Larrey D; Box T; Yoshida E; Lawitz E; Buggisch P; Ferenci P; Weltman M; Labriola-Tompkins E; Le Pogam S; Nájera I; Thomas D; Hooper G; Shulman NS; Zhang Y; Navarro MT; Lim CY; Brunda M; Terrault NA; Yetzer ES
Gastroenterology; 2013 Oct; 145(4):790-800.e3. PubMed ID: 23811112
[TBL] [Abstract][Full Text] [Related]
10. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
Lawitz E; Poordad F; Kowdley KV; Cohen DE; Podsadecki T; Siggelkow S; Larsen L; Menon R; Koev G; Tripathi R; Pilot-Matias T; Bernstein B
J Hepatol; 2013 Jul; 59(1):18-23. PubMed ID: 23439262
[TBL] [Abstract][Full Text] [Related]
11. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Gane EJ; Pockros PJ; Zeuzem S; Marcellin P; Shikhman A; Bernaards C; Zhou J; Yetzer ES; Ballester R; Dwyer C; Tong X; Nájera I; Bertasso A; Hammond J; Kindrick A; Morcos PN; Smith P; Stancic S; Shulman NS
Liver Int; 2015 Jan; 35(1):79-89. PubMed ID: 24814388
[TBL] [Abstract][Full Text] [Related]
12. Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1b hepatitis C infection.
Xiao L; Wu X; Zhang F; Wang J; Xu X; Li L
J Med Virol; 2020 Dec; 92(12):3516-3524. PubMed ID: 32525562
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Pan S; Feng K; Huang P; Zeng Y; Ke L; Yang X; Liu J; Lin C
Medicine (Baltimore); 2021 Jun; 100(24):e26312. PubMed ID: 34128871
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
[TBL] [Abstract][Full Text] [Related]
15. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
Everson G; Cooper C; Hézode C; Shiffman ML; Yoshida E; Beltran-Jaramillo T; Andreone P; Bruno S; Ferenci P; Zeuzem S; Brunda M; Le Pogam S; Nájera I; Zhou J; Navarro MT; Voulgari A; Shulman NS; Yetzer ES
Liver Int; 2015 Jan; 35(1):108-19. PubMed ID: 24517252
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Forestier N; Larrey D; Marcellin P; Guyader D; Patat A; Rouzier R; Smith PF; Qin X; Lim S; Bradford W; Porter S; Seiwert SD; Zeuzem S
J Infect Dis; 2011 Aug; 204(4):601-8. PubMed ID: 21791662
[TBL] [Abstract][Full Text] [Related]
17. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.
Gane EJ; Rouzier R; Stedman C; Wiercinska-Drapalo A; Horban A; Chang L; Zhang Y; Sampeur P; Nájera I; Smith P; Shulman NS; Tran JQ
J Hepatol; 2011 Nov; 55(5):972-9. PubMed ID: 21354234
[TBL] [Abstract][Full Text] [Related]
18.
Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis.
Kao JH; Tung SY; Lee Y; Thongsawat S; Tanwandee T; Sheen IS; Wu JJ; Li H; Brennan BJ; Zhou J; Le Pogam S; Najera I; Thommes JA; Hill G
J Gastroenterol Hepatol; 2016 Oct; 31(10):1757-1765. PubMed ID: 26992248
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
